Advanced Biomed (NASDAQ: ADVB) to buy Acellent in $1.08M stock transaction
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Advanced Biomed Inc. entered into a Share Purchase Agreement to acquire Acellent Technologies (Hong Kong) Co. Limited, which provides AI-powered financial verification and audit solutions. The seller will receive 270,000 shares of Advanced Biomed common stock, valued at $4.00 per share, for an estimated total of $1,080,000.
The acquisition is conditioned on completing financial and legal due diligence of Acellent and obtaining all required regulatory approvals, so the transaction has not yet closed.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Purchase price shares: 270,000 shares
Estimated share value: $4.00 per share
Aggregate estimated value: $1,080,000
+2 more
5 metrics
Purchase price shares
270,000 shares
Consideration for 100% of Acellent equity
Estimated share value
$4.00 per share
Estimated value of Advanced Biomed common stock used as consideration
Aggregate estimated value
$1,080,000
Total estimated value of stock consideration for the acquisition
Agreement date
April 2, 2026
Date of Share Purchase Agreement execution
Equity interest acquired
100%
Portion of Acellent Technologies equity to be purchased
Key Terms
Material Definitive Agreement, Share Purchase Agreement, regulatory approvals, financial and legal due diligence, +1 more
5 terms
Material Definitive Agreement regulatory
"Item 1.01 Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
regulatory approvals regulatory
"receipt of any and all regulatory approvals required in connection with the Acquisition."
Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.
financial and legal due diligence financial
"completion of financial and legal due diligence reviews of the Target"
Common Stock financial
"270,000 shares of the Company’s common stock, par value $0.001 per share"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
What acquisition did Advanced Biomed Inc. (ADVB) announce in this 8-K?
Advanced Biomed Inc. agreed to acquire Acellent Technologies (Hong Kong) Co. Limited. Acellent provides AI-powered financial verification and audit solutions, and Advanced Biomed plans to purchase 100% of its equity under a Share Purchase Agreement dated April 2, 2026.
How is Advanced Biomed (ADVB) paying for the Acellent Technologies acquisition?
Advanced Biomed will pay entirely in stock, issuing 270,000 shares of its common stock. These shares are estimated at $4.00 per share, giving the transaction an aggregate estimated value of $1,080,000 under the Share Purchase Agreement.
What conditions must be met before Advanced Biomed’s acquisition of Acellent closes?
Closing depends on completing financial and legal due diligence of Acellent and receiving all required regulatory approvals. Until these conditions are satisfied, the acquisition remains pending and may not be completed as initially contemplated.
What type of solutions does Acellent Technologies provide to Advanced Biomed (ADVB)?
Acellent Technologies is described as a Hong Kong company engaged in providing AI-powered financial verification and audit solutions. These services focus on using artificial intelligence to support financial review and auditing processes for clients.